Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

 
• By Joseph Haas

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Superbug strain bacteria concept as a killer microbe shaped as a death skull face as a symbol for MRSA medical healthcare risk and antimicrobial health hazard as a 3D illustration on white. - Illustration
Scynexis wants to position Brexafemme to fight fungal infections with high mortality

More from Strategy

More from Business